Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midomafetamine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
Details : MDMA (3,4-methylenedioxymethamphetamine) is being evaluated in mid-stage clinical trials for the treatment of PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Midomafetamine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Steven & Alexandra Cohen Foundation
Deal Size : $5.0 million
Deal Type : Funding
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
Details : The grant provides MAPS with vital mission support as it enters the final stages of the drug development process for MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for the treatment of PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Steven & Alexandra Cohen Foundation
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this first Phase 3 trial of any psychedelic-assisted therapy, participants who received MDMA-assisted therapy reported a significant reduction in PTSD symptoms vs those who received placebo with therapy, achieving the prespecified primary endpoint for...
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable